Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating baricitinib to see if it can preserve beta-cell function in children and adults newly diagnosed with type 1 diabetes. This Phase 3 randomized, double-blind, placebo-controlled study includes participants aged 1 to under 36 years who have been recently diagnosed with type 1 diabetes. The study aims to understand the impact of baricitinib on insulin-producing cells to potentially support better diabetes management. Participants will be randomly assigned to receive either oral baricitinib or a placebo. The treatment period lasts up to 52 weeks, during which participants will take their assigned study medication regularly. The study compares the effects of baricitinib against placebo to assess preservation of beta-cell function and related outcomes. Throughout the approximately 60-week participation, individuals will undergo multiple assessments including measuring C-peptide levels, hemoglobin A1c, insulin use, hypoglycemic events, growth parameters, and quality of life surveys. Safety and drug levels will also be monitored. These evaluations help researchers determine how the study drug affects diabetes control and participant health over time.
Actively Recruiting
Researchers are evaluating cardiac performance by comparing stroke-volume-index measurements taken by three different methods in patients undergoing and recovering from cardiac surgery. The study focuses on patients after cardiac surgery who have a pulmonary artery catheter and involves monitoring during surgery and in the intensive care unit, including both ventilated and spontaneously breathing patients. The study assesses cardiac performance using three diagnostic tools the pulmonary artery catheter, FloTrac, and the Argos Monitor. These devices measure cardiac output and stroke-volume-index by different mechanisms. Investigations are conducted in the operating theater and intensive care unit to observe measurements under various patient conditions. Participants will be monitored for stroke volume index over a 24-hour period following surgery. The study collects data using these devices without altering patient treatment. Researchers will evaluate and compare the measurements to understand differences among the methods. This observational study does not include treatments or interventions beyond standard care, and participation duration depends on the postoperative monitoring period.
Actively Recruiting
This trial focuses on patients who have undergone implantation of a durable left ventricular assist device LVAD and are being monitored using a pulmonary artery catheter. The study aims to compare the effects of two different ventilation methods on heart function, particularly the right ventricle. Researchers are evaluating hemodynamic changes between extra thoracic negative pressure ventilation and traditional intrathoracic positive pressure ventilation in this patient group. Participants will first receive ventilation using negative pressure ventilation for 15 minutes, followed by ventilation with positive pressure ventilation. Both ventilation modes are applied sequentially to each participant while hemodynamic parameters are measured. The study does not include a placebo or control group but compares the two ventilation techniques within the same individuals. During the study, participants will be closely monitored using a pulmonary artery catheter to assess right ventricular function and other hemodynamic changes. The main outcome measure is the right ventricular stroke work index RVSWI recorded during one minute of ventilation. The total duration of the study participation is dependent on the ventilation period and monitoring immediately after LVAD implantation. Safety and stability of participants are carefully observed throughout the procedure.